Differentiation of induced pluripotent stem cells into functional oligodendrocytes

GLIA

Volumn 59, Issue 6, 2011, Pages 882-892

  Czepiel, Marcin ^a   Balasubramaniyan, Veerakumar ^a   Schaafsma, Wandert ^a   Stancic, Mirjana ^a   Mikkers, Harald ^b   Huisman, Christian ^a   Boddeke, Erik ^a   Copray, Sjef ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cell lineage; Multiple sclerosis; Pluripotency; Remyelination

Indexed keywords

ANIMAL CELL; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CELL CULTURE; CELL DIFFERENTIATION; CELL MATURATION; CELL STRUCTURE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; OLIGODENDROGLIA; PLURIPOTENT STEM CELL; PRIORITY JOURNAL;

ANIMALS; BRAIN TISSUE TRANSPLANTATION; CELL CULTURE TECHNIQUES; CELLS, CULTURED; COCULTURE TECHNIQUES; FIBROBLASTS; INDUCED PLURIPOTENT STEM CELLS; MICE; MICE, INBRED C57BL; OLIGODENDROGLIA; RATS; RATS, WISTAR; STEM CELL TRANSPLANTATION; TRANSFECTION;

EID: 79954606776     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.21159     Document Type: Article

References (42)

1. Aasen T, Raya A, Barrero MJ, Garreta E, Consiglio A, Gonzalez F, Vassena R, Bilic J, Pekarik V, Tiscornia G, Edel M, Boue S, Izpisua Belmonte JC. 2008. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat Biotechnol 26: 1276-1284.
2. Barberi T, Klivenyi P, Calingasan NY, Lee H, Kawamata H, Loonam K, Perrier AL, Bruses J, Rubio ME, Topf N, Tabar V, Harrison NL, Beal MF, Moore MA, Studer L. 2003. Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice. Nat Biotechnol 21: 1200-1207.
3. Ben-Hur T, Einstein O, Mizrachi-Kol R, Ben-Menachem O, Reinhartz E, Karussis D, Abramsky O. 2003. Transplanted multipotential neural precursor cells migrate into the inflamed white matter in response to experimental autoimmune encephalomyelitis. Glia 41: 73-80.
4. Bjartmar C, Wujek JR, Trapp BD. 2003. Axonal loss in the pathology of MS: Consequences for understanding the progressive phase of the disease. J Neurol Sci 206: 165-171.
5. Brustle O, Jones KN, Learish RD, Karram K, Choudhary K, Wiestler OD, Duncan ID, McKay RD. 1999. Embryonic stem cell-derived glial precursors: A source of myelinating transplants. Science 285: 754-756.
6. Colman A, Dreesen O. 2009. Pluripotent stem cells and disease modeling. Cell Stem Cell 5: 244-247.
7. Cooper B, Chebib M, Shen J, King NJ, Darvey IG, Kuchel PW, Rothstein JD, Balcar VJ. 1998. Structural selectivity and molecular nature of L-glutamate transport in cultured human fibroblasts. Arch Biochem Biophys 353: 356-364.
8. Copray S, Balasubramaniyan V, Levenga J, de BJ, Liem R, Boddeke E. 2006. Olig2 overexpression induces the in vitro differentiation of neural stem cells into mature oligodendrocytes. Stem Cells 24: 1001-1010.
9. DeSilva TM, Kabakov AY, Goldhoff PE, Volpe JJ, Rosenberg PA. 2009. Regulation of glutamate transport in developing rat oligodendrocytes. J Neurosci 29: 7898-7908.
10. Einstein O, Fainstein N, Vaknin I, Mizrachi-Kol R, Reihartz E, Grigoriadis N, Lavon I, Baniyash M, Lassmann H, Ben-Hur T. 2007. Neural precursors attenuate autoimmune encephalomyelitis by peripheral immunosuppression. Ann Neurol 61: 209-218.
11. Filippi M, Bozzali M, Rovaris M, Gonen O, Kesavadas C, Ghezzi A, Martinelli V, Grossman RI, Scotti G, Comi G, Falini A. 2003. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 126: 433-437.
12. Glaser T, Perez-Bouza A, Klein K, Brustle O. 2005. Generation of purified oligodendrocyte progenitors from embryonic stem cells. FASEB J 19: 112-114.
13. Hu BY, Du ZW, Li XJ, Ayala M, Zhang SC. 2009. Human oligodendrocytes from embryonic stem cells: Conserved SHH signaling networks and divergent FGF effects. Development 136: 1443-1452.
14. Ishikawa Y, Onoyama I, Nakayama KI, Nakayama K. 2008. Notch-dependent cell cycle arrest and apoptosis in mouse embryonic fibroblasts lacking Fbxw7. Oncogene 27: 6164-6174.
15. Kipp M, Clarner T, Dang J, Copray S, Beyer C. 2009. The cuprizone animal model: New insights into an old story. Acta Neuropathol 118: 723-736.
16. Liu S, Qu Y, Stewart TJ, Howard MJ, Chakrabortty S, Holekamp TF, McDonald JW. 2000. Embryonic stem cells differentiate into oligodendrocytes and myelinate in culture and after spinal cord transplantation. Proc Natl Acad Sci U S A 97: 6126-6131.
17. Magalon K, Cantarella C, Monti G, Cayre M, Durbec P. 2007. Enriched environment promotes adult neural progenitor cell mobilization in mouse demyelination models. Eur J Neurosci 25: 761-771.
18. Martino G, Franklin RJ, Van Evercooren AB, Kerr DA. 2010. Stem cell transplantation in multiple sclerosis: Current status and future prospects. Nat Rev Neurol 6: 247-255.
19. Mason JL, Toews A, Hostettler JD, Morell P, Suzuki K, Goldman JE, Matsushima GK. 2004. Oligodendrocytes and progenitors become progressively depleted within chronically demyelinated lesions. Am J Pathol 164: 1673-1682.
20. Matsushima GK, Morell P. 2001. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 11: 107-116.
21. Miller RH. 2002. Regulation of oligodendrocyte development in the vertebrate CNS. Prog Neurobiol 67: 451-467.
22. Nistor GI, Totoiu MO, Haque N, Carpenter MK, Keirstead HS. 2005. Human embryonic stem cells differentiate into oligodendrocytes in high purity and myelinate after spinal cord transplantation. Glia 49: 385-396.
23. O'Malley J, Woltjen K, Kaji K. 2009. New strategies to generate induced pluripotent stem cells. Curr Opin Biotechnol 20: 516-521.
24. Onorati M, Camnasio S, Binetti M, Jung CB, Moretti A, Cattaneo E. 2010. Neuropotent self-renewing neural stem (NS) cells derived from mouse induced pluripotent stem (iPS) cells. Mol Cell Neurosci 43: 287-295.
25. Park IH, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A, Lensch MW, Cowan C, Hochedlinger K, Daley GQ. 2008a. Disease-specific induced pluripotent stem cells. Cell 134: 877-886.
26. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, Lerou PH, Lensch MW, Daley GQ. 2008b. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451: 141-146.
27. Pluchino S, Quattrini A, Brambilla E, Gritti A, Salani G, Dina G, Galli R, Del CU, Amadio S, Bergami A, Furlan R, Comi G, Vescovi AL, Martino G. 2003. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature 422: 688-694.
28. Saha K, Jaenisch R. 2009. Technical challenges in using human induced pluripotent stem cells to model disease. Cell Stem Cell 5: 584-595.
29. Scheper W, Copray S. 2009. The molecular mechanism of induced pluripotency: A two-stage switch. Stem Cell Rev 5: 204-223.
30. Sher F, van DG, Boddeke E, Copray S. 2009. Bioluminescence imaging of Olig2-neural stem cells reveals improved engraftment in a demyelination mouse model. Stem Cells 27: 1582-1591.
31. Stuve O, Bennett JL, Hemmer B, Wiendl H, Racke MK, Bar-Or A, Hu W, Zivadinov R, Weber MS, Zamvil SS, Pacheco MF, Menge T, Hartung HP, Kieseier BC, Frohman EM. 2008. Pharmacological treatment of early multiple sclerosis. Drugs 68: 73-83.
32. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. 2007. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861-872.
33. Takahashi K, Yamanaka S. 2006. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663-676.
34. Tallantyre EC, Bo L, Al-Rawashdeh O, Owens T, Polman CH, Lowe JS, Evangelou N. 2010. Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis. Mult Scler 16: 406-411.
35. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. 1998. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338: 278-285.
36. Uccelli A, Mancardi G. 2010. Stem cell transplantation in multiple sclerosis. Curr Opin Neurol 23: 218-225.
37. Warren L, Manos PD, Ahfeldt T, Loh YH, Li H, Lau F, Ebina W, Mandal PK, Smith ZD, Meissner A, Daley GQ, Brack AS, Collins JJ, Cowan C, Schlaeger TM, Rossi DJ. 2010. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7: 618-630.
38. Woodruff RH, Tekki-Kessaris N, Stiles CD, Rowitch DH, Richardson WD. 2001. Oligodendrocyte development in the spinal cord and telencephalon: Common themes and new perspectives. Int J Dev Neurosci 19: 379-385.
39. Yamanaka S. 2008. Induction of pluripotent stem cells from mouse fibroblasts by four transcription factors. Cell Prolif 41(Suppl 1): 51-56.
40. Yin L, Velazquez OC, Liu ZJ. 2010. Notch signaling: Emerging molecular targets for cancer therapy. Biochem Pharmacol 80(5): 690-701.
41. Yu J, Vodyanik MA, Smuga-Otto K, ntosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA. 2007. Induced pluripotent stem cell lines derived from human somatic cells. Science 318: 1917-1920.
42. Yuan JS, Kousis PC, Suliman S, Visan I, Guidos CJ. 2010. Functions of notch signaling in the immune system: Consensus and controversies. Annu Rev Immunol 28: 343-365.